Tag results:
Industry & Policy News
Cancer Stem Cell News
Senate Panel Approves 2% Bump for NIH Budget in 2024
[Science Insider] Although below the rate of biomedical inflation, it is far more generous than a corresponding House of Representatives bill that would slash NIH’s budget by 6%.
Cell Therapy News
Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the US Food and Drug Administration (FDA) for LYMPHIRâ„¢ (Denileukin Diftitox) for the Treatment of...
[Citius Pharmaceuticals, Inc.] Citius Pharmaceuticals, Inc. announced that the US FDA has issued a Complete Response Letter regarding the Company's Biologics License Application seeking approval for denileukin diftitox.
Cell Therapy News
FDA Grants Fast Track Designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma
[Invectys, Inc.] Invectys, Inc. announced the US FDA has granted Fast Track designation to its revolutionary product, IVS-3001, a CAR-T cell immunotherapy that targets the rarely exploited immune checkpoint and tumor-specific antigen known as HLA-G.
Muscle Cell News
Engineered Cardiac Tissues to Fly on Northrop Grumman Resupply Mission to Advance Treatments for Heart Disease
[ISS National Lab] Researchers at Emory University will leverage the International Space Station National Laboratory to continue examining how microgravity affects the growth and function of cardiomyocytes as they mature into tissue-like structures.
Hepatic Cell News
Legal Challenges Multiply to Law Reshaping Mexico’s Science Funding System
[SCIENCEINSIDER] Mexico’s controversial new science law, which seeks to reshape government research funding and governance, is facing a flurry of legal challenges.
Intestinal Cell News
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase II Trial of Novel Anti-TL1A Antibody RVT-3101 in...
[Telavant] Telavant announced the initiation of the TAHOE study, a Phase II clinical trial of RVT-3101 for the treatment of moderate to severely active Crohn's disease, with the first patient dosed.